PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 type a plus sign (+) inside this box  $\longrightarrow$   $\boxed{+}$ 

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/689,937 **Application Number** TRANSMITTAL Filing Date 10/11/00 **FORM** First Named Inventor Fred Christians SER 2 5 2001 1655 (to be used for all correspondence after initial filing) Group Art Unit TECH CENTER 1600/2900 S. Zitomer **Examiner Name** Total Number of Pages in This Submission 9 Attorney Docket Number 3299.1 ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers Fee Transmittal Form Group (for an Application) Appeal Communication to Board of Fee Attached Drawing(s) Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Proprietary Information Petition After Final Petition to Convert to a Status Letter Affidavits/declaration(s) Provisional Application Power of Attorney, Revocation Other Enclosure(s) Extension of Time Request Change of Correspondence Address (please identify below): Sequence listing in paper (2 Terminal Disclaimer pages) and computer readable Express Abandonment Request form (1 floppy diskette). Request for Refund ☐ Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Wei Zhou, Reg. No. 44,419 Individual name Signature September 014, 2001 Date **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

September 15, 2001

Date

September 15, 2001

addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Sandra E. Wells

andly 4

Typed or printed name

Signature

# SEP 2 5 7001 TECH CENTER 1600/2900

SEP

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached.
2. This application does not conform exclusively to the requirements of §§ 1.821 throug 1.825. The non-conforming material should be deleted. § 1.821(b).
3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:
a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically:
b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.
c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically:
d. Other:
5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).
6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).
7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically:
8. A statement that the content of the paper and computer readable copies are the same not been submitted as required by § 1.821(f).
9. The amendment to or replacement of the paper and/or computer readable copies of the Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).
10. The computer readable form that has been filed with this application has been found be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer led. § 1.825(d). Specifically:
11. Other:
PPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THE L

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of the may be obtained by filing a petition accompanied by the extension fee under the provisions of 7 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A copy of this notice MUST be returned with your response.



Attorney Docket No.3299.1

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fred Christians et al.

Serial No: 09/689,937

Filing Date:

October 11, 2000

Title: PREPARATION OF NUCLEIC ACID SAMPLES

Commissioner for Patents Washington, D.C. 20231

Sir:

Examiner: S. Zitomer

RECEIVED

Group Art Unit: 1655

SEP 2 5 2001

TECH CENTER 1600/2900

**RESPONSE TO** RESTRICTION REQUIREMENT

In response to the Restriction Requirement mailed August 15, 2001, Applicants elect to prosecute claims 1-48 in Group I, drawn to a method of making nucleic acids, classified in class 435, subclass 6. Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the inventions of Group II (Claims 49-55), Group III (Claims 56-68) and Group IV (Claim 69). Applicants do not hereby abandon or waive any rights in the inventions of Groups II, III and IV.

In a preliminary amendment submitted herewith Claim 16 has been amended to remove SEQ ID NOS: 1-8 making the requirement for an election of nucleic acid sequence moot.

#### SEQUENCE LISTING

Transmitted herewith is a copy of the "Sequence Listing" (2 sheets) in paper form for the above identified patent application and a copy of the "sequence listing" in computer readable form. In addition, as required by 37 C.F.R. 1.821(f), a statement that the content of the "Sequence Listing" in paper form and the computer readable form of

the "Sequence Listing" are the same is also transmitted herewith. Applicants' attorney asserts that the submission includes no new matter.

Please insert the attached "Sequence Listing" comprising SEQ ID NOS: 1-8 into the above referenced application.

#### **CONCLUSION**

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 408-731-5699.

Dated: September, 2001

Respectfully submitted,

Wei Zhou

Reg. No. 44,419

Legal Department Affymetrix, Inc. 3380 Central Expressway Santa Clara, CA 95051

Tel: 408/731-5699 Fax: 408/731-5392